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3Different Types of Hemoglobin Cause Sickle Cell Disease
www.nhlbi.nih.gov/health/health-topics/topics/sca
Sickle hemoglobin 
(HbS) causes the red 
blood cells to stick 
inside narrow blood 
vessels, thus blocking 
blood flow and 
oxygen supply 
Normal hemoglobin 
(HbA) allows the red 
blood cells to flex 
and flow through 
narrow blood vessels 
without getting stuck
Different types of hemoglobin (i.e., hemoglobin variants) affect how 
red blood cells (RBC) function 
● The type of hemoglobin inherited through our genes determines whether a person 
has sickle cell disease and the type of sickle cell disease 
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4Types of Hemoglobin and Sickle Cell Disease, 
Sickle Cell Anemia and Sickle Cell Trait
“Sickle cell disease” has different combinations of
hemoglobin variants
● Hemoglobin S/S or “sickle cell anemia”
● Hemoglobin S/b0 thalassemia
● Hemoglobin S/C
● Hemoglobin S/b+ thalassemia
“Sickle cell trait” is when one sickle gene is present
● Individuals with trait typically do not have any symptoms
● Two parents with trait may have a child with sickle cell disease
● Genetic counseling, including awareness of trait status, is important
5Sickle Cell Disease (SCD) Throughout The World
Piel FB, Hay SI, Gupta S, et al. PLoS Med. 2013;10(7)
Worldwide about 300,000 annual births
● 79% infants born with sickle cell occur in sub-Saharan Africa
Mortality is associated with access to prevention and health care 
● In the U.S., over 95% of children with SCD live past the age of 18
● In low-income and middle-income countries, about 90% of children
die before the age of 5
Access to public health infrastructure, universal screening programs, 
and specific medical interventions could lower global mortality 
6What Are Symptoms and Outcomes of Sickle Cell Disease?
When blood flow is blocked, sudden and severe pain arises
● Episodes are called “sickle cell crises” or “pain crises”
Sickle cell crises can be life threatening
● In the brain, can cause strokes
● In the lungs, can cause acute chest syndrome
Sickle cell disease can cause chronic organ damage
● In the spleen, impairs immune function
● In the bones, can result in avascular necrosis
● In the kidneys, can result in chronic renal failure
Severity and lifelong impact of sickle cell disease is difficult to predict
7Increased Premature Mortality Related to Sickle Cell Disease
Death Rate Among Those With Sickle Cell Disease 2004–2008, (annualized), 
African Americans, and Total U.S. Population, 2008
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8Understanding Who Has Sickle Cell Disease (SCD) 
Is Important To Improving Outcomes
Hassell, KL. Am J Prev Med. 2010 Apr;38(4 Suppl):S512-21
Sickle cell disease can be life-
threatening even at young ages
Newborn screening for SCD 
in all 50 states
● 1,500–2,000 babies are 
identified each year
Approximately 100,000 
Americans are affected
● No national registries to 
understand how to improve outcomes
Estimated Number of 
Individuals per State
Distribution of Individuals with SCD 
in United States, 2008
9Understanding Sickle Cell Disease Through Surveillance
Registry and Surveillance System for Hemoglobinopathies (RuSH), 2010–2012 
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Research, Epidemiology and Surveillance 
Continued through PHRESH
RuSH: Registry and Surveillance System for Hemoglobinopathies
Public Health Research, Epidemiology, and Surveillance for 
Hemoglobinopathies (PHRESH) project was launched as next step
● Designed to evaluate and validate RuSH methods
● Conducted from 2012–2014
Disseminate findings from RuSH
● Families, healthcare providers, policymakers
Sites included California, Georgia 
and Mississippi 
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Moving Forward: Sickle Cell Data Collection (SCDC) Program
www.cdc.gov/ncbddd/hemoglobinopathies/scdc.html
Collect, synthesize and disseminate multi-source, population-based, 
longitudinal data for people with sickle cell disease (SCD) 
1. Establish a health profile of the SCD population 
2. Track changes in SCD outcomes over time
3. Ensure credible, scientifically sound information to inform standards of care
4. Inform policy and health care practices
Improve quality of life, life expectancy, 
and health among those living with SCD
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SCDC Data Will Include Up to 10% of the U.S. SCD Population
SCDC: Sickle Cell Data Collection
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Vital Records 
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SCDC Next Steps
Disseminate findings
● Peer-reviewed publications, scientific 
presentations, social media, policy briefs
Include additional states
● Establish training institute to help other 
states develop population-based 
surveillance system for sickle 
cell disease 
Secure additional sustained 
support and funding
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Thank You to SCDC Partners, Families, and Participants
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The Sickle Cell Community and
Pediatric Care for SCD
Kim Smith-Whitley, MD
Chief Medical Officer (Immediate Past)
Sickle Cell Disease Association of America, Inc.
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Historical Perspective
Sickle cell disease is an inherited hemoglobinopathy
Characterized by hemolysis, vascular occlusion
Unpredictable clinical complications such as acute 
pain, life-threatening infection, stroke and acute 
chest syndrome (i.e., pneumonia-like illness)
In 1971, Sickle Cell Disease Association 
of America formed
In 1972, the National Sickle Cell 
Anemia Control Act passed Helped found the Sickle Cell Disease 
Association of America 
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Dramatic Improvement for Children Given Oral Penicillin 
Prophylaxis to Prevent Pneumococcal Infection
Gaston MH, Verter JI, Woods G, et al. N Engl J Med. 1986 Jun 19;314(25):1593-9
Cumulative Infection Rates for All Patients in the Prophylactic Penicillin Study
Study 
recommended 
penicillin 
prophylaxis 
start at 
age 4 months  
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Penicillin Prophylaxis Breakthrough
Lent Urgency to Newborn Screening
Infection prophylaxis meant 
infants with SCD needed 
to be identified early  
Newborn screening
● Universal screening recommended 
by NIH in 1987
● State-by-state adoption of screening
● By 2006, all states screening at birth
Specialized vaccine programs
● Pneumococcal vaccines developed
Benson JM, Therrell BL Jr. Semin Perinatol. 2010 Apr;34(2):134-44
Consensus Development Conference Statement, Sep 29-Oct 1 1986
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8 year-old Female 9 year-old Male 6 year-old Male
RMCA LMCA RMCA
Who Is At Risk for Stroke?
RMCA: Right middle cerebral artery                                                                                           LMCA: Left middle cerebral artery
Adams R, McKie V, Nichols F, et al. N Engl J Med. 1992 Feb 7;326(9):605-10
Transcranial Doppler Ultrasonography (TCD) in 3 Siblings with SCD-SS
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Transfusion Therapy for Primary Stroke Prevention
in SCD STOP Trial
Adams RJ, McKie VC, Hsu L, et al. N Engl J Med. 1998 Jul 2;339(1):5-11
Background
● Chronic red blood cell transfusions reduce recurrent stroke rate in 
children with SCD
● Transcranial Doppler ultrasonography (TCD) detects children at risk for stroke
Hypothesis: Could children who have increased risk of stroke be 
helped by transfusions before a stroke occurs?
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Transfusion Therapy Reduces Risk of 
Primary and Secondary Stroke in Sickle Cell Disease
Adams RJ, McKie VC, Hsu L, et al. N Engl J Med. 1998 Jul 2;339(1):5-11
92% reduction in stroke risk, (P < 0.001)
Chronic transfusion therapy greatly 
reduces the risk of first stroke in 
children with SCD-SS who have  
repeatedly abnormal transcranial 
Doppler ultrasonography results
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Painful crises occurred later in patients receiving hydroxyurea than in those receiving 
placebo, and the effect was evident in less than six months
Hydroxyurea Therapy Proven
23
Hydroxyurea Works for SCD-SS 
Thornburg CD, Files BA, Luo Z, et al. Blood. 2012 Nov 22;120(22):4304-10
Hydroxyurea is not FDA approved for use in children
Adverse Event
Hydroxyurea Placebo
Events
Pt. Years=100
Subjects
N=52
Events
Pt. Years=96
Subjects
N=49
Pain Alone 31 17 46 24
Dactylitis 6 4 35 14
Acute Chest 3 3 10 7
Hospitalization 80 31 149 43
Transfusion 11 6 27 14
Splenic Sequestration 3 2 10 7
Sepsis 0 0 3 3
24
Hydroxyurea Works for SCD-SS 
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Bone Marrow Transplantation Cures Sickle Cell Disease
26
Transplantation Can Cure Sickle Cell Disease
Walters MC, Patience M, Leisenring W, et al. N Engl J Med. 1996 Aug 8;335(6):369-76 
Kaplan–Meier Estimates of Survival and Event-free Survival after Bone 
Marrow Transplantation in 22 Patients with Sickle Cell Disease
As of 2016, 
over 1,000 
individuals have 
received 
transplants  
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Approach to Pediatric Treatment
Prevent complications before 
they occur
● Penicillin prophylaxis 
● Transcranial Doppler
Prevent recurrence 
of complication 
● Hydroxyurea therapy
● Chronic transfusion therapy 
● Bone marrow transplantation
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Sickle Cell Disease:  Milestones
Infection 
Prevention
1986
NIH Newborn 
Screening 
Conference
1987
Stroke 
Prevention 
and 
Transfusion 
Therapy
1998
Hydroxyurea
Therapy
1995
Bone Marrow 
Transplantation
1996
Sickle Cell 
Disease 
Treatment Act
2003
Sickle Cell
Prevention Act
1972
SCDAA
established
1971
TCD and 
High Risk
Stroke
1992
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Sickle Cell Disease Association of America: 
Common Agenda and Goals
Increased access to high-quality 
health care across the lifespan
Drug development, therapies 
and programs
● Improve quality of life
● Decrease disease-related complications
Research towards a cure accessible 
for all people with sickle cell disease
30
SCDAA’s Get Connected
Sickle Cell Disease Registry Initiative
Establish a network to distribute information related to clinical care, 
research, health services, health policy, and advocacy
● Children, adults, and families living with sickle cell disease and sickle cell trait
● SCDAA member organizations, and other community-based organizations
● Health care providers and other stakeholders
Establish a mechanism to support care coordination
Develop online communities for information sharing and 
psychosocial support
31
Get Connected: Activities and Early Results
Identify, educate, and train community health workers 
● 35 community health workers trained
Connect children and adults to services if not connected
Enroll children and adults with sickle cell disease in Get Connected 
● 3,152 children and adults enrolled in 15 states
Funding Opportunity Announcement: HRSA-11-031
www.scdfc.org/what-is-get-connected.html
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Sickle Cell Disease: Challenges and Opportunities
Advances in pediatrics, but few across the lifespan
● Lack of data decreases ability to identify health care and policies to best support 
those with sickle cell disease
Get Connected and Sickle Cell Data Collection project will identify, 
inform, and fill gaps 
Limited access to healthcare professionals with expertise in sickle 
cell disease
● Not just for children but for transition and adult care
● High mortality rate in young adult group
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SCDAA SCDNBS Program CBOs 
HRSA
Dr. Donnell Ivy
Andrea Williams
National Institute for Healthcare Quality
Dr. Suzette Oyeku
Dr. Scott Berns
American College of Medical Genetics 
Dr. Amy Brower
National SCDAA HRSA Project
Sonja L Banks
Sonya Ross
Meghan Ringgold
Leroy Hughes, Jr.
Working towards healthier lives for children 
and adults with sickle cell 
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Improving Outcomes for Adults with Sickle Cell Disease
Kathryn Hassell,  MD
Professor of Medicine, Division of Hematology
University of Colorado Denver
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Important Aspects of Adult Sickle Cell Disease
Premature death and mortality
Burden of chronic organ damage
Health care access and utilization
36
Premature Death in Sickle Cell Disease 
Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Blood. 2010 Apr                                                 Steinberg MH, Barton F, Castro O, et al. JAMA. 2003 Apr
Platt OS, Brambilla DJ, Rosse WF, et al. N Engl J Med. 1994 Jun                                                    Wierenga KJ, Hambleton IR, Lewis NA. Lancet. 2001 Mar
Charache S, Terrin ML, Moore RD, et al. N Engl J Med. 1995 May
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Surveillance Identifies Previously Missed Individuals
NCHS: National Center for Health Statistics                                                                                  MCOD: Multiple causes of death
Paulukonis ST, Eckman JR, Snyder AB, et al. Public Health Rep. 2016 Mar-Apr;131(2):367-75
Number of Deaths of People with Sickle Cell Disease from Three 
Data Sources, Georgia and California, 2004–2008
0
20
40
60
80
100
120
140
160
0–4 5–14 15–24 25–34 35–44 45–54 55–64 65–74 >= 75
Age at Death, in years
Population Based 
Surveillance
MCOD 
Mortality Data 
NCHS Compressed 
Mortality Data 
Mean age 
at death: 
42.2 years
N
u
m
b
e
r 
o
f 
D
e
at
h
s
>
38
0
5
10
15
20
25
30
<1 1-4 5-9 10-14 15-19 20-24 25-34 35-44 45-54 55-64 65-74 75-84 85+
1979
(n=301)
2006
(n=483)
2014
(n=504)
Surveillance Can Assess Impact of Childhood Interventions
Update of Hassell, Am J Prev Med, 2010 on May 2016 http://wonder.cdc.gov
Percent of Deaths by Age at Death for Individuals with Sickle Cell Disease
P
e
rc
e
n
t 
o
f 
D
e
at
h
s
Age at Death by Age Group
39
Limitations of the Sickle Cell Data Collection (SCDC) System
Whole population data can provide important information, 
but results must be interpreted with caution
SCDC does not distinguish type of sickle cell disease for each person
● Type of hemoglobin can affect course of sickle cell disease 
Significant differences in premature death related to type of sickle 
cell disease
● Overestimates lifespan in more severe types
● Underestimates lifespan in milder types
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Limitations of the Sickle Cell Data Collection (SCDC) System
Not all interventions are applied to all 
forms of sickle cell disease
● Hydroxyurea is of proven benefit in HbSS
and HbSβothalassemia
● 40% of people have other types of sickle 
cell disease and thus would not be given 
this intervention
May miss important gains in care and 
outcomes made within a given subset
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Adult SCD: Chronic Organ Damage
Manci EA, Culberson DE, Yang YM, et al. Br J Haematol. 2003 Oct;123(2):359-65
Powars DR, Chan LS, Hiti A, et al. Medicine (Baltimore). 2005 Nov;84(6):363-76
Autopsy Study (1929–1996) 
● Evidence of chronic organ injury in 
74% of 306 cases
● Chronic organ damage second most 
common cause of death after 
infection, in >18 year-olds
Cohort Study, N=1,056 patients 
with 40-year follow-up 
● 73% with chronic organ damage 
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Chronic Organ Damage Likely Now Leading Cause of Death
Adapted from Hamideh D and Alvarez O. Pediatr Blood Cancer. 2013 Sep;60(9):1482-6
CDC multiple causes death certificate 
data, 1999–2009
Only 20% died during acute crisis
Common premorbid conditions are 
often seen in sickle cell disease (SCD)
● Congestive heart failure
● Hypertension
● Pneumonia/Acute chest syndrome
60%16%
15%
9%
Cardiopulmonary Renal
Infection Stroke
Most Common Causes of Death by System 
Among People with SCD, 1999–2009
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Population Surveillance Reveals Course of Disease
Blinder MA, Vekeman F, Sasane M, et al. Pediatr Blood Cancer. 2013 May;60(5):828-35 
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Population Surveillance Reveals Use of Interventions
Blinder MA, Vekeman F, Sasane M, et al. Pediatr Blood Cancer. 2013 May;60(5):828-35 
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Increased Use of the Emergency Department Begins in Adolescence
EDR: Emergency department reliance = total emergency department visits/total ambulatory [outpatient + ED] visits
Blinder MA, Duh MS, Sasane M, et al. J Emerg Med. 2015 Oct;49(4):513-522
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Sickle Cell Data Collection (SCDC): Clarifying the Course of Disease
Longitudinal tracking
● Onset and progression of complications
● Use and impact of complication-specific 
and overall disease-modifying therapy
Limitation: SCDC does not distinguish 
type of sickle cell disease
● Rate and severity of complications varies 
between types of sickle cell disease
● Some disease-modifying therapies (e.g., hydroxyurea) 
are used only for some types of sickle cell disease (HbSS and HbSβothalassemia) 
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Adult Healthcare Access and Utilization
Bundy DG, Muschelli J, Clemens GD, et al. Pediatr Blood Cancer. 2012 Nov;59(5):888-94
Oft-stated assumption is that all children with sickle cell disease 
receive comprehensive sickle cell care from sickle cell providers
● Maryland Medicaid data: 38% of children had not seen a hematologist by age 2
Adult health care is often characterized as nonexistent, inaccessible, 
or rendered by providers without knowledge or interest
● Mostly based on anecdote, not data
● Increase in complications, ED utilization, mortality in early adulthood said to be 
evidence for this, but data suggest change actually occurs in adolescence
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Insurance Is Not the Same as Access
Few adults with sickle cell disease are truly 
uninsured (<5%), but:
● May not cover necessary services
● Limited or no access to expert providers
● High-deductible plans may preclude use
Intermittent loss of coverage
● Loss of employment – lose employer-based plans
● Gain of employment – no longer eligible for 
Medicaid, Medicare, or disability coverage
hcupnet.ahrq.gov/HCUPnet.jsp, National Inpatient Sample report, run 21 May 2016 
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Role of Self-Determination
McLaughlin JF, Ballas SK. Transfusion. 2016 May;56(5):1014-21
Evaluation in adult sickle cell program, 1993–2009
● 22 patients with history of overt stroke on chronic transfusion
● Mean age at transition (transfer): 22 years old
● Mortality: 36% (8/22) within 5 years
 All who died actively 
refused transfusion or 
stopped coming 
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Opportunities and Limitations of Sickle Cell Data Collection
Identify sites of care and use during 
the critical period of adolescence and 
young adulthood
● Observe disease course while still in 
pediatric care, without change in provider
However, lack of use may not mean 
lack of access
● Data regarding referrals, arranged transfers 
and scheduled appointments that were not 
kept are not captured
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Important Aspects of the Sickle Cell Data Collection Program
Population-level data regarding
● Premature death
● Disease course
● Impact of interventions
● Healthcare utilization
Identify providers and sites of care
Data can be used to develop strategies to 
prevent and reduce the burden of sickle cell 
disease and its complications
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A Health Policy Approach to Sickle Cell Disease
Associate Professor of Pediatrics
Baylor College of Medicine
Director, Center for Child Health Policy and Advocacy 
Texas Children’s Hospital
Jean L. Raphael, MD, MPH
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Objectives
Describe current guiding principles in health care policy
Identify policy challenges in sickle cell disease 
Outline a policy agenda for sickle cell disease
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Triple Aim for Population Health
Berwick DM, Nolan TW, Whittington J. Health Affairs. 2008 May-June;27(3):759-769
1.Reduce costs
● Eliminate overuse or misuse of 
diagnostic tests or therapies
2.Improve population health
● Identify systematic variations in care 
or outcomes 
● Apply knowledge to develop policies 
for improvement
3.Enhance patient experience
● Actively survey patient experience
● Involve patients and families in system redesign
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Road Map of High-Quality Care Leads to Improved Outcomes
Dougherty D, Conway PH. JAMA.  2008. 299(19):2319-2321
Clinical 
Effectiveness 
Knowledge
Clinical 
Efficacy
Knowledge
Basic 
Biomedical 
Science
Improved 
health care 
quality, and 
value, and 
population 
health
Key T1 Activity: 
Test what care works
1. Clinical Efficacy Research
T1
Key T2 Activity: 
Test who benefits 
from promising care
1. Outcomes Research
2. Comparative Effectiveness 
Research
3. Health Services Research
T2
Key T3 Activity: 
Test how to deliver high-quality 
care reliably and in all settings
1. Measurement and accountability 
of health care quality and cost
2. Implementation of interventions 
and health care system design
3. Scaling and spread of 
effective interventions
4. Research in above domains
T3
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Healthy People 2020
www.healthypeople.gov/2020/topics-objectives/topic/blood-disorders-and-blood-safety/objectives
Hemoglobinopathies were previously well represented
Focus on treatment 
● Screening for complications, and disease-modifying therapies
Focus on access to medical home, community resources, and 
educational support
These objectives were retired because 
existing data systems could not assess them!
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Advances in Care Are Opportunities to Improve Outcomes
TCD: Transcranial Doppler ultrasonography 
Advances in care
● Hydroxyurea
● TCD screening for stroke risk
● Chronic transfusions
Extended life expectancy
● In 1973, life expectancy was 14 years
● In 2008, life expectancy was 42 years
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Challenges Remain to Improve Outcomes
Persistently high resource use
● Especially for acute care
High risk of mortality at early adulthood
● Transition to adult care
Poorly studied population 
Poor funding and organizing relative to other conditions
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Challenges for Further Research in SCD
Lack of data sources with adequate 
numbers of people with SCD or 
sufficient clinical detail
Limited evidence base for 
management guidelines
Limited number of dedicated 
clinical providers
www.nhlbi.nih.gov/files/docs/guidelines/sc_mngt.pdf
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Agenda for Sickle Cell Disease: Research and Policy
Population health and big data
Comparative effectiveness 
research of treatments
Technology-based interventions
● Outreach through technology that 
patients are already using
(e.g., health apps) 
Development of new 
funding strategies
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Agenda for Sickle Cell Disease: Healthcare Delivery
ECHO: Extension for Community Healthcare Outcomes,  echo.unm.edu
Arora S, Geppert CM, Kalishman S, et al. Acad Med. 2007 Feb;82(2):154-60
Building medical neighborhoods
● Primary care providers and specialists
collaborate to manage patients 
Supporting adult providers 
with expertise (e.g., ECHO Model)
Modifying existing 
reimbursement models
● Reimbursement for care coordination
Addressing social determinants of health
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What Do We Need Now?
Health care policy strategies are needed to fully realize benefits of 
basic and clinical science advancements for sickle cell disease (SCD)
Strategies must align with current priorities in reforming health 
care system
Policy solutions in SCD should be patient-centered, provider-centered, 
and health system-oriented
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Improving the Lives of People with Sickle Cell Disease
Continue progress in advancing care 
● Translating research into treatment and practice 
Use data to identify gaps in care
● Variability in disease course and management
● Availability, use, and access to care
● Transitions from pediatric to adult care, and for adult care
Need more support to meet healthcare needs
● Connect people to care
● Understand better which care is best for each individual
● Better systems to provide patient-centered care 
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